Kindly prepare answers as per MD medicine university exam,add flow charts and diagrams Long Answer Question a. Write the classification of Systemic Vasculitis. Discuss the clinical features and management of ANCA associated vasculitis. b. Discuss approach to a patient of fever with thrombocytopenia. Write its managements. ve. Classify Pneumonia. Discuss management of Hospital acquired pneumonia and its complications. 2. Short Question 1)Neurological involvement in HIV. 2)Newer treatment modalities of Diabetes mellitus? 3)Clinical picture, diagnosis and managemenit of Acute leukemia. 4)Antiviral Vaccines 5)DOTS plus 6)diagnostic tools to confirm obesity 7)Acromegaly 8)Discuss Anti epileptic drug.

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have excellent textbook content. Let me compile all three long answer questions comprehensively with flowcharts and diagrams in ASCII/text format.

MD MEDICINE UNIVERSITY EXAM ANSWERS

LONG ANSWER QUESTION 1(a)

Classification of Systemic Vasculitis + ANCA-Associated Vasculitis

CLASSIFICATION OF SYSTEMIC VASCULITIS

The currently accepted classification is based on the 2012 Revised International Chapel Hill Consensus Conference (CHCC) Nomenclature, organized primarily by vessel size.

┌─────────────────────────────────────────────────────────────────────────┐
│         CLASSIFICATION OF SYSTEMIC VASCULITIS (CHCC 2012)              │
├────────────────────┬────────────────────────────────────────────────────┤
│  VESSEL SIZE       │  DISEASE ENTITIES                                  │
├────────────────────┼────────────────────────────────────────────────────┤
│                    │  • Giant Cell Arteritis (GCA) — temporal artery    │
│  LARGE VESSEL      │  • Takayasu Arteritis — aorta + main branches      │
│  (Aorta & major    │    ("Pulseless disease", young Asian females)       │
│   branches)        │                                                    │
├────────────────────┼────────────────────────────────────────────────────┤
│                    │  • Polyarteritis Nodosa (PAN)                      │
│  MEDIUM VESSEL     │    — visceral arteries, spares lung                │
│  (Main visceral    │  • Kawasaki Disease                                │
│   arteries)        │    — coronary arteries, children                   │
├────────────────────┼────────────────────────────────────────────────────┤
│                    │  ANCA-Associated Vasculitis (AAV):                 │
│  SMALL VESSEL      │    • Granulomatosis with Polyangiitis (GPA)        │
│  (Arterioles,      │    • Microscopic Polyangiitis (MPA)                │
│   capillaries,     │    • Eosinophilic GPA (EGPA/Churg-Strauss)         │
│   venules)         │  Immune Complex Mediated:                          │
│                    │    • IgA Vasculitis (HSP)                          │
│                    │    • Cryoglobulinemic Vasculitis                   │
│                    │    • Hypocomplementemic Urticarial Vasculitis       │
│                    │    • Anti-GBM Disease (Goodpasture)                │
├────────────────────┼────────────────────────────────────────────────────┤
│  VARIABLE VESSEL   │  • Behcet Disease                                  │
│                    │  • Cogan Syndrome                                  │
├────────────────────┼────────────────────────────────────────────────────┤
│  SINGLE ORGAN      │  • Cutaneous leukocytoclastic vasculitis           │
│                    │  • Primary CNS vasculitis                          │
├────────────────────┼────────────────────────────────────────────────────┤
│  SECONDARY         │  • Lupus vasculitis, RA vasculitis                 │
│  VASCULITIS        │  • Drug-induced, infection-associated              │
└────────────────────┴────────────────────────────────────────────────────┘

Features by Vessel Size (Table)

Organ	Small Vessel	Medium Vessel	Large Vessel
Skin	Palpable purpura	Livedo reticularis	Cyanosis
Renal	Hematuria, RBC casts, proteinuria	Hematuria, flank pain	Hypertension
GI	GI bleeding	Bowel perforation	Bowel infarction
Neuro	Polyneuropathy	Mononeuritis multiplex, strokes	Strokes

(Washington Manual of Medical Therapeutics)

ANCA-ASSOCIATED VASCULITIS (AAV)

AAV comprises three entities all associated with anti-neutrophil cytoplasmic antibodies (ANCA), causing necrotizing small-to-medium vessel inflammation without immune complex deposition.

ANCA Types

ANCA Type	Pattern	Target Antigen	Associated Disease
c-ANCA	Cytoplasmic	PR3 (Proteinase 3)	GPA (Wegener's)
p-ANCA	Perinuclear	MPO (Myeloperoxidase)	MPA, EGPA

1. Granulomatosis with Polyangiitis (GPA) - Formerly Wegener's

Pathology: Granulomatous necrotizing vasculitis of small and medium vessels

Clinical Features

┌─────────────────────────────────────────────────────┐
│        GPA: CLINICAL TRIAD                          │
│                                                     │
│  UPPER RESPIRATORY     LOWER RESPIRATORY    KIDNEY  │
│  ┌───────────────┐     ┌──────────────┐  ┌───────┐  │
│  │ • Sinusitis   │     │ • Pulmonary  │  │ Rapid │  │
│  │ • Nasal       │     │   nodules    │  │ Progr.│  │
│  │   crusting    │     │ • Cavitation │  │ GN    │  │
│  │ • Saddle nose │     │ • Hemoptysis │  │(RPGN) │  │
│  │ • Septal      │     │ • DAH        │  │       │  │
│  │   perforation │     │              │  │       │  │
│  │ • Nasal polyps│     │              │  │       │  │
│  └───────────────┘     └──────────────┘  └───────┘  │
└─────────────────────────────────────────────────────┘

Other features:

Palpable purpura, papulonecrotic skin lesions
"Strawberry gingivitis" - oral mucosal involvement
Subglottic stenosis
Sensorineural hearing loss / otitis media
Retroorbital mass - proptosis
Mononeuritis multiplex
PR3-ANCA (c-ANCA) positive in ~90% with renal disease; ~60% without
Limited GPA - only granulomatous features without vasculitic features

2. Microscopic Polyangiitis (MPA)

Key difference from GPA: Non-granulomatous (no sinusitis, no mass lesions)

Clinical Features:

Rapidly progressive glomerulonephritis (RPGN) - most common
Diffuse alveolar hemorrhage (DAH)
Palpable purpura
Mononeuritis multiplex
MPO-ANCA (p-ANCA) positive in ~70%
Biopsy: Necrotizing vasculitis without immune complex deposition or granuloma

3. Eosinophilic Granulomatosis with Polyangiitis (EGPA) - Churg-Strauss

Classic Three-Phase Progression:

PHASE 1 (Prodrome)       PHASE 2 (Eosinophilic)      PHASE 3 (Vasculitic)
      │                          │                           │
Allergic rhinitis         Peripheral eosinophilia      Mononeuritis multiplex
Asthma (>90%)            >1000 cells/μL               Palpable purpura
Nasal polyps             Pulmonary infiltrates         Glomerulonephritis
Atopy                    (migratory ground glass)      Eosinophilic myocarditis
                         Eosinophilic                  (accounts for ~50% deaths)
                         gastroenteritis

Unique Features:

Asthma in >90% — often severe, precedes vasculitis by years
Peripheral eosinophilia (hallmark, >1000/μL) - not seen in GPA/MPA
Eosinophilic myocarditis - arrhythmia/heart failure
MPO-ANCA positive in ~40% only (ANCA-negative more common in EGPA)
Allergic rhinitis + nasal polyps

DIAGNOSTIC APPROACH TO AAV

SUSPECTED AAV
     │
     ▼
Clinical features (sinusitis, hemoptysis, hematuria, purpura)
     │
     ▼
Labs: CBC, CMP (Cr/BUN), urinalysis (RBC casts!)
ANCA serology: c-ANCA/PR3, p-ANCA/MPO
CXR / HRCT chest
     │
     ├─── ANCA positive + Classic Clinical + No alternate diagnosis
     │          │
     │          ▼
     │    Likely diagnosis - Start treatment
     │
     └─── ANCA negative / Uncertain
                │
                ▼
          BIOPSY affected organ
          (kidney, lung, sinus, skin)
          Findings: Necrotizing vasculitis
          without immune complex deposits
          ± granulomata (GPA/EGPA)

Key Lab Values:

Elevated ESR, CRP
Elevated serum creatinine (renal involvement)
Urinalysis: hematuria, proteinuria, RBC casts (most important)
Anemia of chronic disease
Peripheral eosinophilia (EGPA specific)
ANCA serology (c-ANCA/PR3 or p-ANCA/MPO)
Chest CT: nodules, cavities, ground-glass opacities

MANAGEMENT OF ANCA-ASSOCIATED VASCULITIS

Management is in two phases: Remission Induction + Remission Maintenance

┌──────────────────────────────────────────────────────────────────┐
│              AAV MANAGEMENT ALGORITHM                            │
│                                                                  │
│  ASSESS SEVERITY                                                 │
│       │                                                          │
│       ├── SEVERE (RPGN, DAH, organ-threatening)                  │
│       │       │                                                  │
│       │       ▼ INDUCTION (3-6 months)                          │
│       │   High-dose Glucocorticoids                              │
│       │   + Rituximab 375 mg/m² q week x4 weeks                 │
│       │   OR Cyclophosphamide 2 mg/kg/day orally                 │
│       │   (If Cr >4 mg/dL or DAH on MV → prefer CYC)            │
│       │   + Pulse methylprednisolone 1g IV x3 days               │
│       │       │                                                  │
│       │       ▼ MAINTENANCE (18-24 months+)                      │
│       │   Rituximab 500 mg q 6 months (preferred)               │
│       │   OR Azathioprine 2 mg/kg/day                            │
│       │   OR Methotrexate 20-25 mg/week                          │
│       │   + Tapering glucocorticoids                             │
│       │                                                          │
│       └── NON-SEVERE (constitutional, skin, mild renal)          │
│               │                                                  │
│               ▼ INDUCTION                                        │
│           Glucocorticoids + Methotrexate OR Rituximab            │
│               │                                                  │
│               ▼ MAINTENANCE                                      │
│           Methotrexate OR Azathioprine                           │
└──────────────────────────────────────────────────────────────────┘

Remission Induction Therapy

Drug	Dose	Notes
Methylprednisolone (IV pulse)	1 g IV × 3 days	For severe organ involvement
Prednisolone	1 mg/kg/day (max 60-80 mg) then taper	Backbone of all regimens
Rituximab	375 mg/m² IV weekly × 4 weeks	Preferred for relapsing disease, fertility concerns
Cyclophosphamide (oral)	2 mg/kg/day (reduce in renal impairment)	Preferred if Cr >4 mg/dL, DAH on MV
Cyclophosphamide (IV pulse)	15 mg/kg q2-3 weeks	Fewer infections vs oral; higher relapse rate

Remission Maintenance Therapy

Drug	Dose	Duration
Rituximab	500 mg IV q6 months	18-24+ months
Azathioprine	2 mg/kg/day	18-24 months
Methotrexate	20-25 mg/week oral/SC	Alternative to AZA
Mycophenolate mofetil	2-3 g/day	Second-line

Additional/Specific Therapies

Plasma exchange (PLEX): Reserved for AAV + anti-GBM antibody disease; evidence questioned for isolated RPGN
EGPA specific: Add Mepolizumab (anti-IL-5 monoclonal antibody) for eosinophilic disease
PCP prophylaxis: Co-trimoxazole (Bactrim DS) during immunosuppression
Osteoporosis prophylaxis: Calcium + Vitamin D + bisphosphonate with long-term steroids
Dialysis: For ESRD resulting from RPGN

(Harrison's Principles of Internal Medicine 22E, Rosen's Emergency Medicine, Firestein & Kelley's Textbook of Rheumatology)

LONG ANSWER QUESTION 1(b)

Approach to a Patient with Fever and Thrombocytopenia

DEFINITION

Fever: Temperature >38°C (100.4°F)
Thrombocytopenia: Platelet count <1,50,000/μL

FLOWCHART: APPROACH TO FEVER WITH THROMBOCYTOPENIA

PATIENT WITH FEVER + THROMBOCYTOPENIA
             │
             ▼
    ┌─── HISTORY ───────────────────────────────────────────────┐
    │  Duration of fever, pattern (remittent/intermittent)      │
    │  Travel history (malaria endemic area, dengue zone)        │
    │  Drug history (heparin, quinine, TMP-SMX, valproate)      │
    │  Tick/animal exposure (RMSF, ehrlichiosis)                │
    │  Bleeding symptoms (petechiae, gum bleeding, hemoptysis)   │
    │  Rash, lymphadenopathy, hepatosplenomegaly                │
    │  Immunosuppression, HIV risk factors                       │
    └────────────────────────────────────────────────────────────┘
             │
             ▼
    ┌─── EXAMINATION ─────────────────────────────────────────┐
    │  Vital signs, temperature pattern                        │
    │  Petechiae / ecchymoses / purpura                        │
    │  Rash (macular/petechial): dengue, typhus, RMSF          │
    │  Lymphadenopathy, hepatosplenomegaly                     │
    │  Jaundice (malaria, leptospirosis, viral hepatitis)      │
    │  Eschar (scrub typhus - look axilla, groin)              │
    │  Bleeding from multiple sites                            │
    └──────────────────────────────────────────────────────────┘
             │
             ▼
    ┌─── INVESTIGATIONS ──────────────────────────────────────┐
    │  FIRST LINE:                                             │
    │  • CBC + PBF (Peripheral Blood Film) — MOST IMPORTANT   │
    │  • Platelet count                                        │
    │  • Malarial parasite smear / RDT (QBC)                  │
    │  • Dengue NS1 antigen / IgM/IgG (Day 1-5: NS1)          │
    │  • Blood culture x2 (bacteremia, typhoid)               │
    │  • LFT, RFT, PT, aPTT, fibrinogen (DIC screen)          │
    │  • Widal test / Typhidot                                 │
    │  • Urine R/M                                             │
    │                                                          │
    │  SECOND LINE (if above negative/clinical suspicion):     │
    │  • Leptospira antibody (MAT), Leptospira IgM             │
    │  • Scrub typhus IgM ELISA / Weil-Felix OX-K              │
    │  • Rickettsia serology (Weil-Felix OX-19, OX-2)          │
    │  • HIV ELISA                                             │
    │  • Viral serology (CMV, EBV, hepatitis B/C)              │
    │  • Bone marrow examination (if leukemia / kala-azar)     │
    │  • ANA, anti-dsDNA (SLE)                                 │
    │  • ADAMTS13 (TTP), direct Coombs (Evans syndrome)        │
    └──────────────────────────────────────────────────────────┘
             │
             ▼
    PERIPHERAL BLOOD FILM — KEY DIAGNOSTIC CLUE

CAUSES OF FEVER WITH THROMBOCYTOPENIA

┌──────────────────────────────────────────────────────────────┐
│         CAUSES OF FEVER + THROMBOCYTOPENIA                   │
├─────────────────────┬────────────────────────────────────────┤
│  INFECTIONS         │  IMMUNOLOGICAL / OTHERS               │
│  (Most common)      │                                        │
├─────────────────────┼────────────────────────────────────────┤
│  Tropical/Endemic:  │  Immune Thrombocytopenia (ITP)         │
│  • Malaria          │    - with secondary infection          │
│  • Dengue fever     │                                        │
│  • Typhoid          │  TTP / HUS                             │
│  • Scrub typhus     │  (Fever + TTP + MAHA +                 │
│  • Rickettsia       │   neuro + renal + low plt)             │
│  • Leptospirosis    │                                        │
│  Viral:             │  DIC (sepsis-induced)                  │
│  • HIV              │                                        │
│  • CMV, EBV         │  SLE with infection                    │
│  • Viral hepatitis  │                                        │
│  • Hantavirus       │  Drug-induced (heparin,                │
│                     │   quinine, TMP-SMX, valproate)         │
│  Bacterial:         │                                        │
│  • Septicemia       │  Leukemia / Lymphoma                   │
│  • Meningococcemia  │  (bone marrow infiltration)            │
│  • Brucellosis      │                                        │
│                     │  Kala-azar (visceral                   │
│  Parasitic:         │   leishmaniasis)                       │
│  • Kala-azar        │                                        │
└─────────────────────┴────────────────────────────────────────┘

PBF FINDINGS AND DIAGNOSIS

PBF Finding	Diagnosis
Ring forms, gametocytes in RBCs	Malaria
Normal morphology + low platelets	Dengue, Typhoid
Schistocytes (helmet cells) + low Hb	TTP/HUS, DIC
Blast cells	Acute leukemia
Atypical lymphocytes	EBV, CMV
Amastigotes in monocytes	Kala-azar
Morulae in neutrophils/monocytes	Ehrlichiosis/Anaplasmosis

MANAGEMENT

A. General Supportive Measures (All Patients)

Admit if platelet <50,000/μL with bleeding, or <20,000/μL
IV access, monitoring of vitals
Avoid NSAIDs, aspirin (worsen bleeding)
Avoid IM injections (risk of hematoma)
Platelet transfusion: if <10,000/μL (prophylactic) or <50,000/μL with active bleeding/procedure
Fresh Frozen Plasma (FFP) if DIC (PT/aPTT prolonged)
Cryoprecipitate if fibrinogen <1.0 g/L

B. Disease-Specific Management

┌───────────────────────────────────────────────────────────────┐
│           DISEASE-SPECIFIC MANAGEMENT                         │
├─────────────────────────────────────────────────────────────── │
│  MALARIA:                                                     │
│  • P. falciparum: IV Artesunate (severe) / Artemether-        │
│    Lumefantrine (non-severe)                                  │
│  • P. vivax/ovale: Chloroquine + Primaquine                   │
│  • Thrombocytopenia resolves with treatment                   │
├───────────────────────────────────────────────────────────────┤
│  DENGUE:                                                      │
│  • No specific antiviral                                      │
│  • Supportive: IV fluids (crystalloids for dengue shock)      │
│  • Platelet transfusion only if <10,000 or active bleeding    │
│  • Monitor hematocrit (rising Ht = plasma leakage)           │
│  • Warning signs: abdominal pain, persistent vomiting,        │
│    bleeding, rapid breathing, restlessness                    │
├───────────────────────────────────────────────────────────────┤
│  TYPHOID:                                                     │
│  • Ceftriaxone 2g IV OD x 10-14 days (drug of choice)        │
│  • Azithromycin 1g OD x 5 days (oral)                        │
│  • Fluoroquinolones (if sensitive)                            │
├───────────────────────────────────────────────────────────────┤
│  SCRUB TYPHUS:                                                │
│  • Doxycycline 100 mg BD x 7 days (drug of choice)           │
│  • Azithromycin (pregnancy, children)                         │
├───────────────────────────────────────────────────────────────┤
│  LEPTOSPIROSIS:                                               │
│  • Mild: Doxycycline 100 mg BD x 7 days                      │
│  • Severe (Weil's): Penicillin G IV OR Ceftriaxone IV        │
├───────────────────────────────────────────────────────────────┤
│  TTP (Thrombotic Thrombocytopenic Purpura):                   │
│  • EMERGENCY - Plasma Exchange (1-1.5x plasma volume/day)    │
│  • Steroids (prednisolone 1 mg/kg/day)                        │
│  • Caplacizumab (anti-vWF) in acquired TTP                   │
│  • NO platelet transfusion (contraindicated, fuels thrombi)  │
├───────────────────────────────────────────────────────────────┤
│  SEPSIS-INDUCED DIC:                                          │
│  • Treat underlying sepsis (broad-spectrum antibiotics)       │
│  • FFP, cryoprecipitate, platelet concentrate as needed       │
│  • Low-dose heparin (controversial)                           │
├───────────────────────────────────────────────────────────────┤
│  ITP (Immune Thrombocytopenic Purpura):                       │
│  • Prednisolone 1-2 mg/kg/day                                 │
│  • IVIG 1 g/kg/day x 2 days (rapid response needed)          │
│  • Eltrombopag / Romiplostim (refractory)                    │
│  • Rituximab (refractory / chronic ITP)                       │
│  • Splenectomy (chronic refractory ITP)                       │
└───────────────────────────────────────────────────────────────┘

LONG ANSWER QUESTION 1(c)

Classification of Pneumonia + HAP Management

CLASSIFICATION OF PNEUMONIA

A. Based on Setting of Acquisition

┌───────────────────────────────────────────────────────────┐
│            CLASSIFICATION OF PNEUMONIA                    │
│                                                           │
│  ┌──────────────────────────────────────────────────┐     │
│  │  1. Community-Acquired Pneumonia (CAP)           │     │
│  │     Acquired outside hospital or within          │     │
│  │     48 hrs of admission                          │     │
│  │     Organisms: S. pneumoniae (most common),      │     │
│  │     H. influenzae, Mycoplasma, Legionella,       │     │
│  │     Chlamydia, viruses                            │     │
│  └──────────────────────────────────────────────────┘     │
│                                                           │
│  ┌──────────────────────────────────────────────────┐     │
│  │  2. Hospital-Acquired Pneumonia (HAP)             │     │
│  │     Occurs >48 hrs after hospital admission,      │     │
│  │     not incubating at time of admission           │     │
│  │     Organisms: Gram-negatives (P. aeruginosa,     │     │
│  │     Klebsiella, Enterobacter, Acinetobacter),     │     │
│  │     MRSA                                          │     │
│  └──────────────────────────────────────────────────┘     │
│                                                           │
│  ┌──────────────────────────────────────────────────┐     │
│  │  3. Ventilator-Associated Pneumonia (VAP)         │     │
│  │     Occurs >48-72 hrs after endotracheal          │     │
│  │     intubation                                    │     │
│  │     Subset of HAP with highest mortality          │     │
│  └──────────────────────────────────────────────────┘     │
│                                                           │
│  ┌──────────────────────────────────────────────────┐     │
│  │  4. Aspiration Pneumonia                          │     │
│  │     Aspiration of oropharyngeal / gastric         │     │
│  │     contents; anaerobes important                 │     │
│  └──────────────────────────────────────────────────┘     │
│                                                           │
│  ┌──────────────────────────────────────────────────┐     │
│  │  5. Immunocompromised Host Pneumonia              │     │
│  │     PCP (Pneumocystis jirovecii), CMV,            │     │
│  │     Cryptococcus, Aspergillus                     │     │
│  └──────────────────────────────────────────────────┘     │
└───────────────────────────────────────────────────────────┘

B. Based on Morphology / Pathology

Type	Morphology	Organisms
Lobar pneumonia	Entire lobe consolidated	S. pneumoniae
Bronchopneumonia	Patchy peribronchial infiltrates	S. aureus, H. influenzae
Interstitial pneumonia	Diffuse interstitial infiltrates	Viruses, Mycoplasma, PCP
Atypical pneumonia	Diffuse, bilateral, "walking pneumonia"	Mycoplasma, Legionella, Chlamydia

C. Based on Causative Agent

Category	Organisms
Bacterial	S. pneumoniae, S. aureus, H. influenzae, K. pneumoniae, P. aeruginosa
Atypical	Mycoplasma, Legionella, Chlamydia
Viral	Influenza, RSV, SARS-CoV-2, Adenovirus
Fungal	PCP, Aspergillus, Cryptococcus
Parasitic	Strongyloides, Ascaris

HOSPITAL-ACQUIRED PNEUMONIA (HAP)

Definition: Pneumonia occurring ≥48 hours after hospital admission that was not incubating at the time of admission.

VAP: A subtype of HAP occurring ≥48-72 hours after endotracheal intubation.

RISK FACTORS FOR HAP

HOST FACTORS                          HOSPITAL FACTORS
• Age >65 years                       • ICU admission
• COPD, chronic lung disease          • Mechanical ventilation
• Altered consciousness/coma          • Prolonged hospitalization
• Malnutrition                        • Prior antibiotic use
• Immunosuppression                   • Supine position
• Dysphagia                           • H2 blockers/PPI use
• NG tube insertion                   • Contaminated respiratory
• Post-operative state                  equipment
• Renal failure                       • Poor hand hygiene

PATHOGENS IN HAP

Early-onset HAP (<5 days): Often non-MDR - S. pneumoniae, H. influenzae, MSSA, sensitive gram-negatives

Late-onset HAP (>5 days) or MDR risk:

Pseudomonas aeruginosa
Klebsiella pneumoniae (ESBL, carbapenem-resistant)
Acinetobacter baumannii
MRSA
Stenotrophomonas maltophilia

DIAGNOSIS OF HAP

Clinical Criteria (Requires ≥2):
┌─────────────────────────────────────┐
│ • New/progressive infiltrate on CXR  │
│ • Fever >38°C OR Hypothermia <36°C  │
│ • Leukocytosis >10,000 OR           │
│   Leukopenia <4,000                 │
│ • Purulent sputum                   │
│ • New/worsening respiratory sx      │
└─────────────────────────────────────┘
          +
Microbiological Confirmation:
• Endotracheal aspirate culture
• BAL quantitative culture (≥10⁵ cfu/mL)
• Protected specimen brush (≥10³ cfu/mL)
• Blood culture (<15% positive in HAP)

Clinical Pulmonary Infection Score (CPIS): Used for HAP diagnosis (score >6 supports diagnosis)

MANAGEMENT OF HAP - FLOWCHART

NEW HAP SUSPECTED
        │
        ▼
Obtain cultures BEFORE antibiotics
(endotracheal aspirate/BAL + blood cultures)
        │
        ▼
   ASSESS MDR RISK FACTORS
   • Prior antibiotic use in last 90 days
   • Hospitalization ≥5 days
   • Prior MRSA colonization
   • High local MDR prevalence
   • Septic shock, structural lung disease
        │
        ├─── LOW MDR RISK + Low mortality risk
        │            │
        │            ▼
        │    MONOTHERAPY (any ONE):
        │    • Piperacillin-tazobactam 4.5g IV q6h
        │    • Cefepime 2g IV q8h
        │    • Levofloxacin 750 mg IV q24h
        │    • Meropenem 1g IV q8h
        │
        └─── HIGH MDR RISK or High mortality risk
                     │
                     ▼
           COMBINATION THERAPY (THREE drugs):
           [Anti-Pseudomonal Beta-lactam]
           + [Anti-Pseudomonal Aminoglycoside/FQ]
           + [Anti-MRSA agent]
           
           Beta-lactam options:
           • Pip-tazo 4.5g IV q6h OR
           • Cefepime 2g IV q8h OR
           • Meropenem 1g IV q8h
           
           Aminoglycoside/FQ options:
           • Amikacin 15-20 mg/kg IV q24h OR
           • Gentamicin 5-7 mg/kg IV q24h OR
           • Levofloxacin 750 mg IV q24h
           
           Anti-MRSA options:
           • Vancomycin 15-20 mg/kg IV q8-12h OR
           • Linezolid 600 mg IV/PO q12h
                     │
                     ▼
           At 48-72 hrs: REVIEW CULTURES
           DE-ESCALATE based on sensitivity

Duration: 7-8 days total (even for P. aeruginosa unless clinical response poor)

ANTIBIOTIC TABLE FOR HAP

Clinical Scenario	Drug of Choice	Alternative
No MDR risk, low mortality	Pip-tazo OR Cefepime (monotherapy)	Levofloxacin
MDR risk present	Pip-tazo/Cefepime/Carbapenem + Aminoglycoside + Vancomycin	Triple therapy
MRSA suspected	Add Vancomycin OR Linezolid	Teicoplanin
Acinetobacter	Carbapenem (imipenem)	Colistin/Polymyxin B
Stenotrophomonas	TMP-SMX (drug of choice)	Levofloxacin
Carbapenem-resistant	Colistin + Carbapenem	Ceftazidime-avibactam

COMPLICATIONS OF HAP

┌──────────────────────────────────────────────────────────────┐
│                COMPLICATIONS OF HAP                          │
├──────────────────────────────────────────────────────────────┤
│                                                              │
│  PULMONARY COMPLICATIONS          EXTRA-PULMONARY            │
│  ━━━━━━━━━━━━━━━━━━━━━━━━         ━━━━━━━━━━━━━━━━━          │
│  • Lung abscess                   • Septicemia / Bacteremia  │
│    (anaerobes, S. aureus)         • Septic shock             │
│                                                              │
│  • Empyema thoracis               • Metastatic abscesses     │
│    (parapneumonic effusion        • Acute Kidney Injury      │
│     → empyema)                                              │
│                                   • Multi-Organ              │
│  • ARDS (Acute Respiratory        Dysfunction Syndrome       │
│    Distress Syndrome)             (MODS)                     │
│    - PaO₂/FiO₂ <200              - Most common cause        │
│    - Bilateral infiltrates          of death in HAP          │
│    - Non-cardiogenic              • DIC                      │
│                                                              │
│  • Respiratory failure            • Endocarditis             │
│    (Type 1 or Type 2)             (S. aureus)                │
│                                                              │
│  • Bronchopleural fistula         • Pericarditis             │
│                                                              │
│  • Pneumothorax                   • DVT / PE                 │
│    (esp. with barotrauma)           (immobilized patients)   │
│                                                              │
│  • Organizing pneumonia           • Nosocomial infections    │
│    / Fibrosis (late)                (UTI, CLABSI)            │
└──────────────────────────────────────────────────────────────┘

PREVENTION OF HAP (Exam Important)

Measure	Mechanism
Head-of-bed elevation 30-45°	Reduces aspiration
Daily sedation holidays	Reduces duration of MV
Oral hygiene / chlorhexidine rinse	Reduces oropharyngeal colonization
Subglottic secretion drainage (SSD) ETT	Reduces microaspiration
Avoid unnecessary H2 blocker/PPI	Reduces gastric pH rise → colonization
Hand hygiene (WHO 5 moments)	Prevents cross-infection
Early enteral nutrition	Maintains gut barrier
VAP bundle (ABCDE bundle)	Reduces VAP rate by 50-70%

SEVERITY ASSESSMENT - PSI / CURB-65

CURB-65 Score (for CAP severity, also guides HAP management):

Parameter	Points
Confusion	1
Urea >7 mmol/L	1
Respiratory rate ≥30/min	1
Blood pressure <90/60 mmHg	1
Age ≥65 years	1

0-1: Outpatient
2: Hospital admission
3-5: ICU consideration

(Harrison's Principles of Internal Medicine 22E, Fishman's Pulmonary Diseases)

References:

Washington Manual of Medical Therapeutics (Vasculitis Classification)

Rosen's Emergency Medicine (ANCA-Associated Vasculitis, clinical features)

Harrison's Principles of Internal Medicine 22E (AAV management, HAP treatment)

Firestein & Kelley's Textbook of Rheumatology (Rituximab/CYC induction)

Fishman's Pulmonary Diseases and Disorders (HAP/VAP)

Robbins & Cotran Pathologic Basis of Disease (Hospital-Acquired Pneumonia)

Kindly make word document

Reading File

Running Command

ls /home/daytona/workspace/ 2>/dev/null && ls /home/daytona/skills/docx/scripts/…

Running Command

mkdir -p /home/daytona/workspace/md-medicine-exam && node -e "require('docx'); c…

This is a shared conversation. Sign in to Orris to start your own chat.